Vanguard Capital Management’s DNA X Inc SONM Stock Holding History

Vanguard Capital Management’s Portfolio SONM Stock Details SONM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.2K	Buy	5,901 +1,009	+21%	+$4.48K	﹤0.01%	3980
2026 Q1	$19.7K	Buy	+4,892	New	+$23.1K	﹤0.01%	3983

Other funds holding SONM

CWM

C2C Wealth Management Scottsdale, Arizona $128M AUM 22.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Vanguard Capital Management's SONM Position: Q2 2026 in Review

Vanguard Capital Management increased its DNA X Inc (SONM) stake by 21% in Q2 2026, buying an estimated $4.48K and bringing the position to 5,901 shares worth $30.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3980.

Vanguard Capital Management first reported a position in SONM in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold SONM as of Q2 2026.

Vanguard Capital Management held 5,901 shares of DNA X Inc worth $30.2K as of Q2 2026.
Vanguard Capital Management bought 1,009 DNA X Inc shares in Q2 2026, an estimated $4.48K.
DNA X Inc made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3980 holding.
Vanguard Capital Management first reported a position in DNA X Inc in Q1 2026 and has held it in 2 quarters since.
9 funds tracked by Wall St. Rank held DNA X Inc as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.